

**NEUROENDOCRINE
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION**

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 3rd, 2014

TIME: 15:00 – 15:30

CHAIRS: DR. TIM ASMIS & DR. HAGEN KENNECKE

- 15:00 WELCOME AND INTRODUCTION **DR. H. KENNECKE AND DR. T. ASMIS**
- 15:05 – 15:10 COMPLETED TRIALS
- NEC.2 (CALGB 80701):** RANDOMIZED PHASE II STUDY OF EVEROLIMUS ALONE VERSUS EVEROLIMUS PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMORS
- DR. H. KENNECKE**
- 15:10 – 15:25 ACTIVE TRIALS
- NEC.3 (ALLIANCE 021202):** PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS **DR. T. ASMIS**
- 15:25 – 15:30 INTERGROUP TASK FORCE UPDATE **DR. T. ASMIS**
- 15:30 CLOSING REMARKS